Drug Trial Radar · NCT00473577
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Last checked: Nov 19, 2026Latest source record: Aug 25, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 2005
Primary completion
Nov 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Pharmacyclics LLC.AbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies. To evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of CRA-024781 IV when administered in a single oral dose.
Conditions
- Hematologic Neoplasms
- Neoplasms
Interventions
CRA-24781Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.